
Owkin Deepens AstraZeneca Partnership With AI-Powered Drug Development Platform
Owkin and AstraZeneca expanded their AI collaboration with a three-year K Pro platform licensing agreement to develop specialized agents for drug development and competitive intelligence.
AZNagentic AIAI agents